Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y462

UPID:
ZN711_HUMAN

ALTERNATIVE NAMES:
Zinc finger protein 6

ALTERNATIVE UPACC:
Q9Y462; B4DSV4; Q6NX42; Q9Y4J6

BACKGROUND:
The Zinc finger protein 711, alternatively named Zinc finger protein 6, is crucial for proper brain development. It likely acts as a transcription factor, binding to target gene promoters and recruiting PHF8 histone demethylase. This process leads to the activated expression of neuron development genes, including KDM5C, showcasing its vital role in the transcriptional regulation mechanism.

THERAPEUTIC SIGNIFICANCE:
Linked to Intellectual developmental disorder, X-linked 97, Zinc finger protein 711's involvement in this disease underscores the importance of its function. Exploring the mechanisms of Zinc finger protein 711 offers promising avenues for developing therapeutic interventions for related intellectual developmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.